CR9870A - Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist - Google Patents

Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist

Info

Publication number
CR9870A
CR9870A CR9870A CR9870A CR9870A CR 9870 A CR9870 A CR 9870A CR 9870 A CR9870 A CR 9870A CR 9870 A CR9870 A CR 9870A CR 9870 A CR9870 A CR 9870A
Authority
CR
Costa Rica
Prior art keywords
prostaglandin
dihydrogen phosphate
phosphate salt
receiver antagonist
antagonist
Prior art date
Application number
CR9870A
Other languages
English (en)
Inventor
Beverly Langevin
Edwuard Orton
Daniel Sherer
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR9870A publication Critical patent/CR9870A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR9870A 2005-10-13 2008-04-07 Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist CR9870A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13

Publications (1)

Publication Number Publication Date
CR9870A true CR9870A (es) 2008-06-18

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9870A CR9870A (es) 2005-10-13 2008-04-07 Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist

Country Status (35)

Country Link
US (1) US7642249B2 (es)
EP (1) EP1948620B1 (es)
JP (1) JP2009511591A (es)
KR (1) KR101365480B1 (es)
CN (1) CN101287714B (es)
AR (1) AR058085A1 (es)
AU (1) AU2006304187B2 (es)
BR (1) BRPI0617311A2 (es)
CA (1) CA2625563C (es)
CR (1) CR9870A (es)
DK (1) DK1948620T3 (es)
DO (2) DOP2006000220A (es)
EC (1) ECSP088362A (es)
ES (1) ES2409833T3 (es)
GT (1) GT200600457A (es)
HN (1) HN2008000603A (es)
HR (1) HRP20130341T1 (es)
IL (1) IL190673A (es)
MA (1) MA30005B1 (es)
MY (1) MY145648A (es)
NI (1) NI200800116A (es)
NO (1) NO20082072L (es)
NZ (1) NZ567433A (es)
PE (1) PE20070791A1 (es)
PL (1) PL1948620T3 (es)
PT (1) PT1948620E (es)
RS (1) RS52799B (es)
RU (1) RU2419614C2 (es)
SI (1) SI1948620T1 (es)
TN (1) TNSN08131A1 (es)
TW (1) TW200728288A (es)
UA (1) UA93062C2 (es)
UY (1) UY29862A1 (es)
WO (1) WO2007047378A2 (es)
ZA (1) ZA200802586B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AR060403A1 (es) * 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
EA200802417A1 (ru) * 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
EP2462110A4 (en) 2009-08-05 2013-04-03 Panmira Pharmaceuticals Llc DP2 ANTAGONIST AND USES THEREOF
US20130123365A1 (en) 2010-07-08 2013-05-16 Ramot At Tel-Aviv University Ltd. Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
US8785467B2 (en) * 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors
CN111094988A (zh) 2017-09-13 2020-05-01 普罗根尼蒂公司 先兆子痫生物标志物及相关系统和方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
JP2005516005A (ja) * 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Ｇｓｋ−３阻害剤として有用なピリミジンベースの化合物
RU2006103655A (ru) * 2003-07-09 2007-08-20 Ф.Хоффманн-Ля Рош Аг (Ch) Тиофениламиноимидазолины
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
DOP2006000223A (es) 2007-05-15
ES2409833T3 (es) 2013-06-28
PT1948620E (pt) 2013-05-06
US20080194600A1 (en) 2008-08-14
DK1948620T3 (da) 2013-06-24
GT200600457A (es) 2007-04-27
RS52799B (sr) 2013-10-31
WO2007047378A2 (en) 2007-04-26
AU2006304187B2 (en) 2011-04-28
JP2009511591A (ja) 2009-03-19
KR101365480B1 (ko) 2014-02-21
AR058085A1 (es) 2008-01-23
AU2006304187A1 (en) 2007-04-26
NI200800116A (es) 2011-12-15
NO20082072L (no) 2008-05-02
CN101287714A (zh) 2008-10-15
MY145648A (en) 2012-03-15
EP1948620B1 (en) 2013-03-20
HN2008000603A (es) 2010-11-03
PE20070791A1 (es) 2007-08-16
UY29862A1 (es) 2007-05-31
US7642249B2 (en) 2010-01-05
TW200728288A (en) 2007-08-01
CA2625563C (en) 2011-04-19
BRPI0617311A2 (pt) 2011-07-19
UA93062C2 (ru) 2011-01-10
CN101287714B (zh) 2011-04-06
DOP2006000220A (es) 2007-05-15
ES2409833T8 (es) 2013-09-26
HRP20130341T1 (en) 2013-05-31
ECSP088362A (es) 2008-05-30
RU2008118491A (ru) 2009-11-20
WO2007047378A3 (en) 2007-08-02
ZA200802586B (en) 2009-09-30
RU2419614C2 (ru) 2011-05-27
NZ567433A (en) 2010-06-25
MA30005B1 (fr) 2008-12-01
CA2625563A1 (en) 2007-04-26
TNSN08131A1 (en) 2009-07-14
SI1948620T1 (sl) 2013-05-31
IL190673A (en) 2011-12-29
EP1948620A2 (en) 2008-07-30
KR20080057275A (ko) 2008-06-24
HK1125133A1 (en) 2009-07-31
IL190673A0 (en) 2008-11-03
PL1948620T3 (pl) 2013-08-30

Similar Documents

Publication Publication Date Title
CR9870A (es) Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist
EP1954290A4 (en) AS KINASE-HEMMER USES TRICYCLIC COMPOUNDS
MA28876B1 (fr) Amides bicycliques comme inhibiteurs de kinases
IL213070A (en) A method for determining the efficacy of PD-1 antagonist
BRPI1008829A2 (pt) forma cristalina de dihidrogenofosfato de (r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
PT2548568T (pt) Ligandos do recetor de melanocortina
ATE449762T1 (de) Kristalline formen einer biphenylverbindung
EP1926221A4 (en) Signal transmitter
ATE479682T1 (de) Kristalline form einer chinolin-carboxamid- verbindung
EP2023727A4 (en) PROSTAGLANDINTRANSPORTER INHIBITORS
BRPI0718444A2 (pt) Inibidores de receptor de adp de plaqueta
EP1935874A4 (en) S1P3 RECEPTOR ANTAGONIST
GB0719707D0 (en) Acoustic generator for measuring distances by echoes
ITPR20070098A1 (it) Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
EP1761562A4 (en) CONFORMATION SPECIFIC ANTIBODIES
PL1723157T5 (pl) Amorficzne postaci rizedronianu monosodowego
GB0525576D0 (en) Determining timing accuracy of a receiver
DE602006003661D1 (de) Ampa-rezeptoren-verstärker
FI20050736A0 (fi) Reaaliaikaisen palvelun laatu
ZA200801431B (en) Solid salt forms of a pyrrole substituted 2-indolinone
FI20040702A0 (fi) Menetelmä fosfaattia sisältävän suspension valmistamiseksi
BRPI0621575A2 (pt) conjunto de peças de conexão para tubos cilindricos para brinquedos de montar em três dimensões
EP1896020A4 (en) SUPPRESSION OF OSTEOLYTIC LESIONS WITH SRC KINASE INHIBITORS
FR2938960B1 (fr) Procede de transmission d'une coordonnee geographique.
DE602005016615D1 (de) Kompensation der parasitären kopplung zwischen hf-ng

Legal Events

Date Code Title Description
FC Refusal